JTV519 (K201) reduces sarcoplasmic reticulum Ca(2+) leak and improves diastolic function in vitro in murine and human non-failing myocardium

BACKGROUND AND PURPOSE

Ca²⁺ leak from the sarcoplasmic reticulum (SR) via ryanodine receptors (RyR2s) contributes to cardiomyocyte dysfunction. RyR2 Ca²⁺ leak has been related to RyR2 phosphorylation. In these conditions, JTV519 (K201), a 1,4-benzothiazepine derivative and multi-channel blocker, stabilizes RyR2s and decrease SR Ca²⁺ leak. We investigated whether JTV519 stabilizes RyR2s without increasing RyR2 phosphorylation in mice and in non-failing human myocardium and explored underlying mechanisms.

EXPERIMENTAL APPROACH

SR Ca²⁺ leak was induced by ouabain in murine cardiomyocytes. [Ca²⁺]-transients, SR Ca²⁺ load and RyR2-mediated Ca²⁺ leak (sparks/waves) were quantified, with or without JTV519 (1 µmol·L⁻¹). Contribution of Ca²⁺-/calmodulin-dependent kinase II (CaMKII) was assessed by KN-93 and Western blot (RyR2-Ser²⁸¹⁴ phosphorylation). Effects of JTV519 on contractile force were investigated in non-failing human ventricular trabeculae.

KEY RESULTS

Ouabain increased systolic and diastolic cytosolic [Ca²⁺]_i, SR [Ca²⁺], and SR Ca²⁺ leak (Ca²⁺ spark (SparkF) and Ca²⁺ wave frequency), independently of CaMKII and RyR-Ser²⁸¹⁴ phosphorylation. JTV519 decreased SparkF but also SR Ca²⁺ load. At matched SR [Ca²⁺], Ca²⁺ leak was significantly reduced by JTV519, but it had no effect on fractional Ca²⁺ release or Ca²⁺ wave propagation velocity. In human muscle, JTV519 was negatively inotropic at baseline but significantly enhanced ouabain-induced force and reduced its deleterious effects on diastolic function.

CONCLUSIONS AND IMPLICATIONS

JTV519 was effective in reducing SR Ca²⁺ leak by specifically regulating RyR2 opening at diastolic [Ca²⁺]_i in the absence of increased RyR2 phosphorylation at Ser²⁸¹⁴, extending the potential use of JTV519 to conditions of acute cellular Ca²⁺ overload.     

Regulation of RYR2 by sarcoplasmic reticulum Ca2+

Ca²⁺ is arguably the most important ion involved in the contraction of the heart. The cardiac ryanodine receptor (RyR2), the major Ca²⁺ release channel located in the sarcoplasmic reticulum (SR) membrane, is responsible for releasing the bulk of Ca²⁺ required for contraction. Moreover, RyR2 is also crucial for maintaining SR Ca²⁺ homeostasis by releasing Ca²⁺ from the SR when it becomes overloaded with Ca²⁺. During normal contraction, RyR2 is activated by cytosolic Ca²⁺, whereas during store overload conditions, the opening of RyR2 is governed by SR Ca²⁺. Although the process of the cytosolic control of RyR2 is well established, the molecular mechanism by which SR luminal Ca²⁺ regulates RyR2 has only recently been elucidated and remains controversial. In addition to the activation of RyR2, SR luminal Ca²⁺ also determines when the RyR2 channel closes. RyR2‐mediated Ca²⁺ release from the SR does not continue until the SR is completely depleted. Rather, it ceases when SR luminal Ca²⁺ falls below a certain level. Given the importance of SR Ca²⁺, it is not surprising that the SR luminal Ca²⁺ level is tightly controlled by SR Ca²⁺‐buffering proteins. Consequently, the opening and closing of RyR2 is heavily influenced by the presence of such proteins, particularly those associated with RyR2, such as calsequestrin and the histidine‐rich Ca²⁺‐binding protein. These proteins appear to indirectly alter RyR2 activity by modifying the microdomain SR Ca²⁺ level surrounding RyR2.     

Sarcoplasmic reticulum and cardiac oxidative stress: an emerging target for heart disease

The sarcoplasmic reticulum (SR) is a major player in maintaining cardiac function, as it is intimately involved in the regulation of Ca²⁺-movements on a beat-to-beat basis. SR dysfunction due to abnormalities in SR protein content has been reported in different cardiac diseases such as ischaemic heart disease, myocardial infarction, congestive heart failure and various cardiomyopathies; thus the genes expressing the SR Ca²⁺-pump, Ca²⁺-channels, calsequestrin, phospholamban and other regulatory proteins are considered important targets for drug development. In our experience, ischaemic preconditioning (IP) and pharmacological therapies, such as anti-oxidants, β-adrenergic receptor blockers, angiotensin receptor (AT-1) blockers, angiotensin converting enzyme inhibitors (ACE-I) and angiotensin receptor blockers are effective therapies that improve cardiac performance in the failing heart by improving SR function. Accordingly, this paper is intended to shed light on the knowledge in the field of cardiac therapy targeted to improve and protect SR function.     

Mechanisms of reduced contractility in an animal model of hypertensive heart failure

1. Alterations in intracellular Ca²⁺ homeostasis have frequently been implicated as underlying the contractile dysfunction of failing hearts. Contraction in cardiac muscle is due to a balance between sarcolemmal (SL) and sarcoplasmic reticulum (SR) Ca²⁺ transport, which has been studied in single cells and small tissue samples. However, many studies have not used physiological temperatures and pacing rates, and this could be problematic given different temperature dependencies and kinetics for transport processes. 2. Spontaneously‐hypertensive rats (SHR) and their age‐matched Wistar Kyoto controls (WKY) provide an animal model of hypertensive failure with many features in common to heart failure in humans. Steady‐state measurements of Ca²⁺ and force showed that peak stress was reduced in trabeculae from failing SHR hearts in comparison to WKY, although the Ca²⁺ transients were bigger and decayed more slowly. 3. Dynamic Ca²⁺ cycling was investigated by determining the recirculation fraction (RF) of activator Ca²⁺ through the SR between beats during recovery from experimental protocols that potentiated twitch force. No difference in RF between rat strains was found, although the RF was dependent on the potentiation protocol used. 4. Superfusion with 10 mmol/L caffeine and 0 mmol/L [Ca²⁺]_o was used to measure SL Ca²⁺ extrusion. The caffeine‐induced [Ca²⁺]_i transient decayed more slowly in SHR trabeculae, suggesting that SL Ca²⁺ extrusion was slower in SHR. 5. An ultrastructural immunohistochemical analysis of left ventricular free wall sections using confocal microscopy showed that t‐tubule organization was disrupted in myocytes from SHR, with reduced labelling of the SR Ca²⁺‐ATPase and Na⁺–Ca²⁺ exchanger in comparison to WKY, with the latter possibly related to a lower fraction of t‐tubules per unit cell volume. 6. We suggest that although Ca²⁺ transport is altered in the progression to heart failure, force development is not limited by the amplitude of the Ca²⁺ transient. Despite slower SR Ca²⁺ transport, the recirculation fraction and dynamic response to a change of inotropic state minimally altered changes in the SHR model because there was a similar slowing in Ca²⁺ extrusion across the surface membrane.     

Istaroxime stimulates SERCA2a and accelerates calcium cycling in heart failure by relieving phospholamban inhibition

Background and Purpose

Calcium handling is known to be deranged in heart failure. Interventions aimed at improving cell Ca²⁺ cycling may represent a promising approach to heart failure therapy. Istaroxime is a new luso-inotropic compound that stimulates cardiac contractility and relaxation in healthy and failing animal models and in patients with acute heart failure (AHF) syndrome. Istaroxime is a Na-K ATPase inhibitor with the unique property of increasing sarcoplasmic reticulum (SR) SERCA2a activity as shown in heart microsomes from humans and guinea pigs. The present study addressed the molecular mechanism by which istaroxime increases SERCA2a activity.

Experimental Approach

To study the effect of istaroxime on SERCA2a-phospholamban (PLB) complex, we applied different methodologies in native dog healthy and failing heart preparations and heterologous canine SERCA2a/PLB co-expressed in Spodoptera frugiperda (Sf21) insect cells.

Key Results

We showed that istaroxime enhances SERCA2a activity, Ca²⁺ uptake and the Ca²⁺-dependent charge movements into dog healthy and failing cardiac SR vesicles. Although not directly demonstrated, the most probable explanation of these activities is the displacement of PLB from SERCA2a.E2 conformation, independently from cAMP/PKA. We propose that this displacement may favour the SERCA2a conformational transition from E2 to E1, thus resulting in the acceleration of Ca²⁺ cycling.

Conclusions and Implications

Istaroxime represents the first example of a small molecule that exerts a luso-inotropic effect in the failing human heart through the stimulation of SERCA2a ATPase activity and the enhancement of Ca²⁺ uptake into the SR by relieving the PLB inhibitory effect on SERCA2a in a cAMP/PKA independent way.     

SERCA2 activity is involved in the CNP-mediated functional responses in failing rat myocardium

BACKGROUND AND PURPOSES

Myocardial C-type natriuretic peptide (CNP) levels are increased in heart failure. CNP can induce negative inotropic (NIR) and positive lusitropic responses (LR) in normal hearts, but its effects in failing hearts are not known. We studied the mechanism of CNP-induced NIR and LR in failing hearts and determined whether sarcoplasmatic reticulum Ca²⁺ ATPase2 (SERCA2) activity is essential for these responses.

EXPERIMENTAL APPROACH

Contractility, cGMP levels, Ca²⁺ transient amplitudes and protein phosphorylation were measured in left ventricular muscle strips or ventricular cardiomyocytes from failing hearts of Wistar rats 6 weeks after myocardial infarction.

KEY RESULTS

CNP increased cGMP levels, evoked a NIR and LR in muscle strips, and caused phospholamban (PLB) Ser¹⁶ and troponin I (TnI) Ser^23/24 phosphorylation in cardiomyocytes. Both the NIR and LR induced by CNP were reduced in the presence of a PKG blocker/cGMP analogue (Rp-8-Br-Pet-cGMPS) and the SERCA inhibitor thapsigargin. CNP increased the amplitude of the Ca²⁺ transient and increased SERCA2 activity in cardiomyocytes. The CNP-elicited NIR and LR were not affected by the L-type Ca²⁺ channel activator BAY-K8644, but were abolished in the presence of isoprenaline (induces maximal activation of cAMP pathway). This suggests that phosphorylation of PLB and TnI by CNP causes both a NIR and LR. The NIR to CNP in mouse heart was abolished 8 weeks after cardiomyocyte-specific inactivation of the SERCA2 gene.

CONCLUSIONS AND IMPLICATIONS

We conclude that CNP-induced PLB and TnI phosphorylation by PKG in concert mediate both a predictable LR as well as the less expected NIR in failing hearts.     

Targeting transgene to the heart and liver with AAV9 by different promoters

Adeno‐associated virus (AAV) has become one of the most promising gene transfer tools for gene therapy. This work aims to evaluate tropism, gene transfer efficiency and safety of AAV9 vectors produced with recombinant baculovirus (rBac)‐based system. AAV9‐CMV‐GFP and AAV9‐CBA‐GFP were produced using a rBac system, 1 × 10¹¹ particles of each vectors were administered intravenously (i.v.) into mice and animals were killed at 1, 2, 3, 4, 5 and 8 weeks after administration. The GFP expression in different organs was analyzed by fluorescence imaging and Western blot. Viral genomic quantities were measured using qPCR. In vitro transduction efficiency of AAV9 vectors in primary cardiomyocytes and hepatocytes was determined by flow cytometry. Toxicity of AAV9 vectors was evaluated by determining certain cardiac and liver injury biomarkers and renal function test in vivo and TUNEL analysis in vitro. The data showed that AAV9 viral particles packaged by the rBac system were fully functional in vivo and in vitro. The CMV promoter predominantly induced higher cardiac GFP transgene expression and DNA copy numbers while the CBA promoter resulted in robust GFP expression and high vector DNA copy numbers in mouse liver, both in a time‐dependent increased manner. Such distinct preferential effects were also observed in the heart and liver as early as 3 and 5 days after co‐infection. Both the AAV9‐CMV and AAV9‐CBA viral packages did not induce heart, liver and renal damage and cell apoptosis. These results indicated that AAV9‐CMV can efficiently and safely direct cardiac gene transfer, whereas AAV9‐CBA is preferential for liver gene delivery.     

Ca2+-calmodulin can activate and inactivate cardiac ryanodine receptors

Background and purpose:

Ca²⁺-calmodulin (Ca²⁺CaM) is widely accepted as an inhibitor of cardiac ryanodine receptors (RyR2); however, the effects of physiologically relevant CaM concentrations have not been fully investigated.

Experimental approach:

We investigated the effects of low concentrations of Ca²⁺CaM (50–100 nmol·L⁻¹) on the gating of native sheep RyR2, reconstituted into bilayers. Suramin displaces CaM from RyR2 and we have used a gel-shift assay to provide evidence of the mechanism underlying this effect. Finally, using suramin to displace endogenous CaM from RyR2 in permeabilized cardiac cells, we have investigated the effects of 50 nmol·L⁻¹ CaM on sarcoplasmic reticulum (SR) Ca²⁺-release.

Key results:

Ca²⁺CaM activated or inhibited single RyR2, but activation was much more likely at low (50–100 nmol·L⁻¹) concentrations. Also, suramin displaced CaM from a peptide of the CaM binding domain of RyR2, indicating that, like the skeletal isoform (RyR1), suramin directly competes with CaM for its binding site on the channel. Pre-treatment of rat permeabilized ventricular myocytes with suramin to displace CaM, followed by addition of 50 nmol·L⁻¹ CaM to the mock cytoplasmic solution caused an increase in the frequency of spontaneous Ca²⁺-release events. Application of caffeine demonstrated that 50 nmol·L⁻¹ CaM reduced SR Ca²⁺ content.

Conclusions and implications:

We describe for the first time how Ca²⁺CaM is capable, not only of inactivating, but also of activating RyR2 channels in bilayers in a CaM kinase II-independent manner. Similarly, in cardiac cells, CaM stimulates SR Ca²⁺-release and the use of caffeine suggests that this is a RyR2-mediated effect.     

The effect of ginseng on heart contraction and sarcoplasmic reticulum function(II)

It was reported from our laboratory that the rate of deterioration of the force of contraction was slower in heart fromPanax ginseng extract treated rats. Present investigation was designed to elucidate the mechanism of the slow deterioration of contractility of ginseng treated hearts. Therefore,⁴⁵Ca²⁺ uptake by sarcoplasmic reticulum (SR) isolated from ginseng treated rats and control rats was studied. Rats weighing 150–250g were administered orally with ginseng ethanol extract (100mg/kg) for 10 days. Cardiac SR was isolated by differential centrifugation and⁴⁵Ca²⁺ uptake was assessed by the Millipore method. Freshly isolated SR from treated as well as control animals did not show any differences, but after incubation for 30 and 60 min at 37°C,⁴⁵Ca²⁺ uptake of control animal SR was found to be greatly depressed. The SR of treated animal possessed a greater degree of resistance to incubation. Thus it can be concluded that ginseng may have an ability to sustain the normal function of the heart by sustaining-Ca accumulation by SR involved with the excitationcontraction coupling processes.     

Electropharmacological effects of intracellular Ca2+ handling modulator caldaret on the heart assessed in the halothane-anesthetized dogs

We analyzed how the enhancement of net sarcoplasmic reticulum (SR) Ca²⁺ uptake may affect cardiac electrophysiological properties in vivo by using caldaret which can decrease SR diastolic Ca²⁺ leak, enhance SR Ca²⁺ reuptake and inhibit reverse-mode Na⁺/Ca²⁺ exchanger. Caldaret in doses of 0.5, 5 and 50 μg/kg was intravenously administered over 10 min to the halothane-anesthetized beagle dogs (n = 5), attaining pharmacologically active plasma concentration. The low and middle doses of caldaret increased the ventricular contraction, which could be explained by its on-target pharmacological activities. The high dose enhanced the sinus automaticity followed by its suppression in addition to the increase of the total peripheral resistance, which may be unfavorable for treating diastolic heart failure. The low and middle doses enhanced the atrioventricular conduction, which may have some potential for predisposing the atria to the onset of atrial fibrillation via an induction of mitral and/or tricuspid regurgitation. The middle and high doses of caldaret prolonged the ventricular effective refractory period without altering the intraventricular conduction or repolarization period, which may prevent the onset of ventricular arrhythmias. Thus, modulation of intracellular Ca²⁺ handling by caldaret can induce not only inotropic effect, but also various electrophysiological actions on the in situ heart.     

Liguzinediol improved the heart function and inhibited myocardial cell apoptosis in rats with heart failure

Aim:

Liguzinediol is a novel derivative of ligustrazine isolated from the traditional Chinese medicine Chuanxiong (Ligusticum wallichii Franch), and produces significant positive inotropic effect in isolated rat hearts. In this study we investigated the effects of liguzinediol on a rat model of heart failure.

Methods:

To induce heart failure, male SD rats were injected with doxorubicin (DOX, 2 mg/kg, ip) once a week for 4 weeks. Then the rats were administered with liguzinediol (5, 10, 20 mg·kg⁻¹·d⁻¹, po) for 2 weeks. Hemodynamic examination was conducted to evaluate heart function. Myocardial cell apoptosis was examined morphologically. The expression of related genes and proteins were analyzed using immunohistochemical staining and Western blot assays, respectively.

Results:

Oral administration of liguzinediol dose-dependently improved the heart function in DOX-treated rats. Electron microscopy revealed that liguzinediol (10 mg·kg⁻¹·d⁻¹) markedly attenuated DOX-induced injury of cardiomyocytes, and decreased the number of apoptotic bodies in cardiomyocytes. Furthermore, liguzinediol significantly decreased Bax protein level, and increased Bcl-2 protein level in cardiomyocytes of DOX-treated rats, led to an increase in the ratio of Bcl-2/Bax. Moreover, liguzinediol significantly decreased the expression of both cleaved caspase-3 and NF-κB in cardiomyocytes of DOX-treated rats. Administration of digitalis (0.0225 mg·kg⁻¹·d⁻¹) also markedly improved the heart function and the morphology of cardiomyocytes in DOX-treated rats.

Conclusion:

Liguzinediol improves the heart function and inhibits myocardial cell apoptosis in the rat model of heart failure, which is associated with regulating Bcl-2, Bax, caspase-3 and NF-κB expression.     

Activation of muscarinic receptors elicits inotropic responses in ventricular muscle from rats with heart failure through myosin light chain phosphorylation

Background and purpose:

Muscarinic stimulation increases myofilament Ca²⁺ sensitivity with no apparent inotropic response in normal rat myocardium. Increased myofilament Ca²⁺ sensitivity is a molecular mechanism promoting increased contractility in failing cardiac tissue. Thus, muscarinic receptor activation could elicit inotropic responses in ventricular myocardium from rats with heart failure, through increasing phosphorylation of myosin light chain (MLC).

Experimental approach:

Contractile force was measured in left ventricular papillary muscles from male Wistar rats, 6 weeks after left coronary artery ligation or sham surgery. Muscles were also frozen, and MLC-2 phosphorylation level was quantified.

Key results:

Carbachol (10 µmol·L⁻¹) evoked a positive inotropic response only in muscles from rats with heart failure approximating 36% of that elicited by 1 µmol·L⁻¹ isoproterenol (20 ± 1.5% and 56 ± 6.1% above basal respectively). Carbachol-evoked inotropic responses did not correlate with infarction size but did correlate with increased left ventricular end diastolic pressure, heart weight/body weight ratio and lung weight, primary indicators of the severity of heart failure. Only muscarinic receptor antagonists selective for M₂ receptors antagonized carbachol-mediated inotropic effects with the expected potency. Carbachol-evoked inotropic responses and increase in phosphorylated MLC-2 were attenuated by MLC kinase (ML-9) and Rho-kinase inhibition (Y-27632), and inotropic responses were abolished by Pertussis toxin pretreatment.

Conclusion and implications:

In failing ventricular muscle, muscarinic receptor activation, most likely via M₂ receptors, provides inotropic support by increasing MLC phosphorylation and consequently, myofilament Ca²⁺ sensitivity. Enhancement of myofilament Ca²⁺ sensitivity, representing a less energy-demanding mechanism of inotropic support may be particularly advantageous in failing hearts.     

A gain of function ryanodine receptor 2 mutation (R1760W-RyR2) in catecholaminergic polymorphic ventricular tachycardia

Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited arrhythmia syndrome associated with Ca²⁺ leak predominantly caused by ryanodine receptor 2 (RyR2) mutations. We identified a R1760W-RyR2 mutation located between the N-terminal domain and the central domain of RyR2 in a CPVT patient by DNA sequencing. Recombinant mutant RyR2_{−2801mcherry} plasmid generated by the overlap extension polymerase chain reaction and seamless cloning was transfected in HEK293 cells for the cell model. Single-cell luminal and cytosolic Ca²⁺ imaging was measured by endoplasmic reticulum (ER) luminal Ca²⁺-sensitive protein D1ER and Fura-2 AM on a confocal laser scanning microscope, respectively. We found that in RyR2 mutant cells, the propensity for store-overload-induced Ca²⁺ release (SOICR) was enhanced representing increased Ca²⁺ oscillations, reduced activation and termination thresholds of spontaneous Ca²⁺ release; and the sensitivity to cytosolic Ca²⁺ activation was increased manifesting reduced steady state ER Ca²⁺ levels. Our results indicated that R1760W-RyR2 mutation induced calcium leak, representing a gain of function. Further, antiarrhythmic drugs propafenone and flecainide significantly suppressed SOICR caused by the R1760W-RyR2 mutation at a concentration of 20 μM, which was lower than the concentration at which carvedilol suppressed SOICR.     

姜黄素防治心力衰竭的药理作用研究进展

心力衰竭是高血压、缺血性心脏病、瓣膜性心脏病、冠心病等各种心血管事件常见的终末期临床表现,病理特征以进行性心功能不全和心肌重塑为主。姜黄素可通过抗心肌肥大和纤维化,增强细胞自噬,降低氧化应激反应,减轻心肌炎性损伤,调节Ca²⁺-ATP酶活性,上调Dickkopf相关蛋白3的表达,多途径防治心力衰竭,进一步阻止心肌重塑,改善心功能。总结了姜黄素防治心力衰竭的研究情况,分析其作用机制,为姜黄素的临床运用提供支持。     

Intracellular calcium channels and their modulators

The ryanodine receptor (RyR) is an essential element in excitation–contraction coupling. Ca²⁺ release from the sarcoplasmic reticulum (SR) is required for skeletal and heart muscle contraction. The inositol-1,4,5-triphosphate-receptor (IP₃R) plays an important function in the signal transduction of many hormones, cytokines, growth factors and antigens, and in fertilisation. Modulators of intracellular calcium channels are used for the treatment of malignant hyperthermia associated with abnormal Ca²⁺ transport and may be applied in the treatment of cardiovascular and neurodegenerative disorders.     

FKBP12 Depletion Leads to Loss of Sarcoplasmic Reticulum Ca2+ Stores in Rat Vas Deferens

The immunophilin 12-kDa FK506 binding protein (FKBP12) stabilizes intracellular Ca²⁺ release channel (CRC) activity in different tissues. In this work, the presence of FKBP12 in rat vas deferens (RVD) and its possible contribution to RVD function was investigated. Treatment under appropriate pH, temperature, and ionic conditions was used to strip FKBP12 from CRC binding sites; Western blotting revealed FKBP12 in control but not in treated homogenates. Disruption of the FKBP12-CRC complex in RVD decreased the Ca²⁺ content of sarcoplasmic reticulum (SR) by increasing Ca²⁺ leakage through the ryanodine receptor (RyR3 isoform) but not through 1,4,5-iNOSitol trisphosphate receptors (IP₃R1 and IP₃R3 isoforms). The decrease of SR Ca²⁺ content was not related to inhibition of SERCA ATPase. It seems that dissociation of FKBP12-RyR leads to conformational changes in RyR that make it difficult for ryanodine to access its binding site. Rapamycin, which is commonly used as a pharmacological tool to disrupt the FKBP12-RyR complex, decreased phenylephrine-induced contractions in RVD epididymal halves. The data suggest that FKBP12 is expressed in RVD in a labile association with RyR3. Disruption of the FKBP12-RyR3 complex may lead to modifications of RVD physiology and in consequence may compromise male fertility.     

The phospholipase C inhibitor U-73122 inhibits Ca2+ release from the intracellular sarcoplasmic reticulum Ca2+ store by inhibiting Ca2+ pumps in smooth muscle

Background and purpose:

The sarcoplasmic reticulum (SR) releases Ca²⁺ via inositol 1,4,5-trisphosphate receptors (IP₃R) in response to IP₃-generating agonists. Ca²⁺ release subsequently propagates as Ca²⁺ waves. To clarify the role of IP₃ production in wave generation, the contribution of a key enzyme in the production of IP₃ was examined using a phosphoinositide-specific phospholipase C (PI-PLC) inhibitor, U-73122.

Experimental approach:

Single colonic myocytes were voltage-clamped in whole-cell configuration and cytosolic Ca²⁺ concentration ([Ca²⁺]_cyto) measured using fluo-3. SR Ca²⁺ release was evoked either by activation of IP₃Rs (by carbachol or photolysis of caged IP₃) or ryanodine receptors (RyRs; by caffeine).

Key results:

U-73122 inhibited carbachol-evoked [Ca²⁺]_cyto transients. The drug also inhibited [Ca²⁺]_cyto increases, evoked by direct IP₃R activation (by photolysis of caged IP₃) and RyR activation (by caffeine), which do not require PI-PLC activation. U-73122 also increased steady-state [Ca²⁺]_cyto and slowed the rate of Ca²⁺ removal from the cytoplasm. An inactive analogue of U-73122, U-73343, was without effect on either IP₃R- or RyR-mediated Ca²⁺ release.

Conclusions and implications:

U-73122 inhibited carbachol-evoked [Ca²⁺]_cyto increases. However, the drug also reduced Ca²⁺ release when evoked by direct activation of IP₃R or RyR, slowed Ca²⁺ removal and increased steady-state [Ca²⁺]_cyto. These results suggest U-73122 reduces IP₃-evoked Ca²⁺ transients by inhibiting the SR Ca²⁺ pump to deplete the SR of Ca²⁺ rather than by inhibiting PI-PLC.     

Dissection of the inhibition of cardiac ryanodine receptors by human glutathione transferase GSTM2-2

The muscle specific glutathione transferase GSTM2-2 inhibits the activity of cardiac ryanodine receptor (RyR2) calcium release channels with high affinity and activates skeletal RyR (RyR1) channels with lower affinity. To determine which overall region of the GSTM2-2 molecule supports binding to RyR2, we examined the effects of truncating GSTM2-2 on its ability to alter Ca²⁺ release from sarcoplasmic reticulum (SR) vesicles and RyR channel activity. The C-terminal half of GSTM2-2 which lacks the critical GSH binding site supported the inhibition of RyR2, but did not support activation of RyR1. Smaller fragments of GSTM2-2 indicated that the C-terminal helix 6 was crucial for the action of GSTM2-2 on RyR2. Only fragments containing the helix 6 sequence inhibited Ca²⁺ release from cardiac SR. Single RyR2 channels were strongly inhibited by constructs containing the helix 6 sequence in combination with adjacent helices (helices 5-8 or 4-6). Fragments containing helices 5-6 or helix 6 sequences alone had less well-defined effects. Chemical cross-linking indicated that C-terminal helices 5-8 bound to RyR2, but not RyR1. Structural analysis with circular dichroism showed that the helical content was greater in the longer helix 6 containing constructs, while the helix 6 sequence alone had minimal helical structure. Therefore the active centre of GSTM2-2 for inhibition of cardiac RyR2 involves the helix 6 sequence and the helical nature of this region is essential for its efficacy. GSTM2-2 helices 5-8 may provide the basis for RyR2-specific compounds for experimental and therapeutic use.     

The ryanodine binding sarcoplasmic reticulum calcium release channel in nonfailing and in failing human myocardium

The ryanodine-sensitive Ca²⁺ release channel (RyaCRC) of the sarcoplasmic reticulum plays a key role in the intracellular Ca²⁺ handling in cardiomyocytes. Altered expression of the RyaCRC has been supposed to contribute to abnormal cellular Ca²⁺ handling and to myocardial dysfunction in dilated and ischemic cardiomyopathy. In the present study the ³H-ryanodine binding site in human myocardial homogenates was characterized and the density of the RyaCRC (which corresponds to the cardiac ryanodine receptor) was determined in nonfailing and in failing human myocardium.Homogenates were prepared from nonfailing left ventricular myocardium from the hearts of 5 organ donors (NF) and from failing myocardium from 14 explanted hearts of transplant recipients with end-stage heart failure resulting from dilated (DCM, n = 5) or ischemic (ICM, n = 9) cardiomyopathy. Radioligand saturation binding experiments revealed a specific, high-affinity ³H-ryanodine binding site (K_d-values: NF: 0.65±0.11 nmol/l, DCM: 0.66±0.09 nmol/l, ICM: 0.88±0.18 nmol/l; n.s.) in all preparations. Specific ³H-ryanodine binding depended on the free Ca²⁺ concentration in the assay. It was maximal at 3–100 mol/l Ca²⁺. The binding was inhibited by the RyaCRC antagonists ruthenium red (K_i-value: 0.32 [0.18–0.56] mol/l, n = 5) and Mg²⁺ (K_i-value: 2.95 [1.23–7.11] mmol/l, n = 5). The RyaCRC density was 103.5±11.9 fmol/mg protein in nonfailing myocardium. There was no significant change in the RyaCRC density in dilated or ischemic cardiomyopathy (112.4±17.1 and 122.7±13.9 fmol/mg protein) compared to nonfailing control myocardium.In summary, ³H-ryanodine binds specifically and with high-affinity to the RyaCRC in human myocardium. There is no change in the RyaCRC density in failing myocardium of patients with DCM or ICM in comparison to nonfailing controls.